Aurora Bay Area Medical Center

Clinical research site in Marinette, Wisconsin · 3003 UNIVERSITY DR, MARINETTE, WI 54143-4110 · (715) 735-1721 · Website

As of July 2026, 47 paid clinical trials are recruiting at Aurora Bay Area Medical Center in Marinette, Wisconsin. Active studies at this site cover conditions such as Anatomic Stage II Breast Cancer AJCC v8, Stage IV Lung Cancer AJCC v8 and Advanced Lung Non-Small Cell Carcinoma. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at Aurora Bay Area Medical Center (47)

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

for Breast Cancer

1105 locations incl. Anchorage

Sponsor: NRG Oncology

Sex: Female·Age: 18 - 60

Code: NCT05879926·Phase 3·Recruiting·Listed May 2023

Apply to this trial

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

for Stage III Colon Cancer

922 locations incl. Fairhope

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT05174169·Phase 2, Phase 3·Recruiting·Listed Dec 2021

Apply to this trial

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

for Anatomic Stage II Breast Cancer AJCC v8

776 locations incl. Fairhope

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT05812807·Phase 3·Recruiting·Listed Apr 2023

Apply to this trial

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

for Anatomic Stage I Breast Cancer AJCC v8

585 locations incl. Phoenix

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT06876714·Phase 3·Recruiting·Listed Mar 2025

Apply to this trial

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

for Intracranial Meningioma

456 locations incl. Anchorage

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT02523014·Phase 2·Recruiting·Listed Aug 2015

Apply to this trial

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

for Advanced Esophageal Adenocarcinoma

643 locations incl. Anchorage

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT05677490·Phase 3·Recruiting·Listed Jan 2023

Apply to this trial

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

for Head and Neck Squamous Cell Carcinoma

466 locations incl. Anchorage

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 18+

Code: NCT02734537·Phase 2·Recruiting·Listed Apr 2016

Apply to this trial

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

for Acute Lymphoblastic Leukemia

631 locations incl. Anchorage

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 40 - 75·Accepts healthy volunteers

Code: NCT05334069·Recruiting·Listed Apr 2022

Apply to this trial

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

for Lung Non-Small Cell Carcinoma

640 locations incl. Anchorage

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04267848·Phase 3·Recruiting·Listed Feb 2020

Apply to this trial

Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects

for Malignancy

405 locations incl. Anchorage

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: All ages

Code: NCT04242095·Recruiting·Listed Jan 2020

Apply to this trial

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

for Smoldering Plasma Cell Myeloma

488 locations incl. Birmingham

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 18+

Code: NCT03937635·Phase 3·Recruiting·Listed May 2019

Apply to this trial

Mobile Health for Adherence in Breast Cancer Patients

for Anatomic Stage IV Breast Cancer AJCC v8

459 locations incl. Kingman

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 18+·Accepts healthy volunteers

Code: NCT06112613·Recruiting·Listed Nov 2023

Apply to this trial

Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors

for Hodgkin Lymphoma

405 locations incl. Anchorage

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 18+

Code: NCT06002828·Recruiting·Listed Aug 2023

Apply to this trial

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

for Anatomic Stage II Breast Cancer AJCC v8

525 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06058377·Phase 3·Recruiting·Listed Sep 2023

Apply to this trial

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

for Muscle Invasive Bladder Urothelial Carcinoma

449 locations incl. Phoenix

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05987241·Phase 2, Phase 3·Recruiting·Listed Aug 2023

Apply to this trial

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

for Previously Treated Non-Small Cell Lung Cancer

950 locations incl. Birmingham

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT03851445·Phase 2, Phase 3·Recruiting·Listed Feb 2019

Apply to this trial

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

for Bladder Adenocarcinoma

224 locations incl. Phoenix

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT03866382·Phase 2·Recruiting·Listed Mar 2019

Apply to this trial

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

for Advanced Malignant Solid Neoplasm

430 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: All ages

Code: NCT05564377·Phase 2·Recruiting·Listed Oct 2022

Apply to this trial

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

for Clear Cell Renal Cell Carcinoma

405 locations incl. Phoenix

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT06661720·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

for Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma

316 locations incl. Gilbert

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT06958328·Phase 3·Recruiting·Listed May 2025

Apply to this trial

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

for Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

382 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 5 - 60

Code: NCT05675410·Phase 3·Recruiting·Listed Jan 2023

Apply to this trial

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

for Acute Myeloid Leukemia

328 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05564390·Phase 2·Recruiting·Listed Oct 2022

Apply to this trial

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

for Advanced Lung Non-Small Cell Carcinoma

266 locations incl. Fayetteville

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 70+

Code: NCT06096844·Phase 3·Recruiting·Listed Oct 2023

Apply to this trial

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

for Locally Advanced Lung Non-Small Cell Carcinoma

446 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT05624996·Phase 3·Recruiting·Listed Nov 2022

Apply to this trial

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers

for Pancreatic Neoplasm

336 locations incl. Birmingham

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 50 - 75

Code: NCT04239573·Recruiting·Listed Jan 2020

Apply to this trial

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

for Advanced Lung Non-Small Cell Carcinoma

222 locations incl. Fairbanks

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT03191149·Phase 2·Recruiting·Listed Jun 2017

Apply to this trial

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

for Recurrent Lung Non-Small Cell Carcinoma

372 locations incl. Daphne

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT05642572·Phase 2·Recruiting·Listed Dec 2022

Apply to this trial

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

for Refractory Differentiated Thyroid Gland Carcinoma

288 locations incl. Anchorage

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 18+

Code: NCT06475989·Phase 3·Recruiting·Listed Jun 2024

Apply to this trial

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

for Renal Pelvis and Ureter Urothelial Carcinoma

152 locations incl. Kingman

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04628767·Phase 2, Phase 3·Recruiting·Listed Nov 2020

Apply to this trial

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

for Recurrent Endometrial Carcinoma

285 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: Female·Age: 18+

Code: NCT05554328·Phase 2·Recruiting·Listed Sep 2022

Apply to this trial

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

for Advanced Esophageal Adenocarcinoma

346 locations incl. Little Rock

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06203600·Phase 2, Phase 3·Recruiting·Listed Jan 2024

Apply to this trial

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

for Lymphoma, Non-Hodgkin

146 locations incl. Birmingham

Sponsor: American Society of Clinical Oncology

Sex: All·Age: 12+

Code: NCT02693535·Phase 2·Recruiting·Listed Feb 2016

Apply to this trial

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

for Prostate Adenocarcinoma

399 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: Male·Age: 18+

Code: NCT05946213·Phase 3·Recruiting·Listed Jul 2023

Apply to this trial

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

for Metastatic Dedifferentiated Liposarcoma

241 locations incl. DeKalb

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06422806·Phase 3·Recruiting·Listed May 2024

Apply to this trial

Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors

for Malignant Solid Neoplasm

588 locations incl. Anchorage

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT04871542·Recruiting·Listed May 2021

Apply to this trial

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

for Metastatic Head and Neck Squamous Cell Carcinoma

170 locations incl. Little Rock

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06589804·Phase 3·Recruiting·Listed Sep 2024

Apply to this trial

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

for Head and Neck Squamous Cell Carcinoma

169 locations incl. Gilbert

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT06992427·Phase 3·Recruiting·Listed May 2025

Apply to this trial

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

for Stage I Breast Cancer

707 locations incl. Mobile

Sponsor: NRG Oncology

Sex: All·Age: 50 - 70

Code: NCT04852887·Phase 3·Recruiting·Listed Apr 2021

Apply to this trial

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

for Recurrent Lung Non-Small Cell Carcinoma

381 locations incl. Daphne

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT06616584·Phase 2, Phase 3·Recruiting·Listed Sep 2024

Apply to this trial

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

for Lung Non-Small Cell Carcinoma

243 locations incl. Jonesboro

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT06116682·Phase 2·Recruiting·Listed Nov 2023

Apply to this trial

Showing the 40 most relevant of 47 recruiting trials at this site. Browse all with filters →

More research sites in Marinette

Aurora Bay Area Medical Group-Marinette (46 trials)

Explore more

Paid clinical trials in Marinette, WI · Wisconsin clinical trials